Merryn Voysey1,2, Andrew J Pollard2,3. 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, United Kingdom. 2. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, United Kingdom. 3. NIHR Oxford Biomedical Research Centre, United Kingdom.
Abstract
Background: Salmonella Typhi is the major cause of enteric fever in lower-income countries. New conjugate vaccines show promise as public health interventions, but there are no efficacy data available from endemic areas. Methods: Data were obtained from a previously published phase 3 randomized controlled trial comparing Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TT) with Vi polysaccharide vaccine (Vi-PS) in participants aged 2-45 years. An additional open-label arm administered Vi-TT to children aged 6-23 months. The proportion of participants with presumed clinical or subclinical infection ("seroincidence") was determined using mixture models and compared using relative risks (RRs). Results:Of 387 participants, 81 (21%) were classified as having presumed typhoid infection during the 2-year postvaccination period. Seroincidence was lower in participants randomized to Vi-TT rather than Vi-PS among those aged 2-45 years (RR, 0.372; 95% confidence interval [CI], .235-.588; P < .001) and those aged 2-15 years (RR, 0.424; 95% CI, .231-.778; P = .004). There was no difference in seroincidence for Vi-TT between those aged 2-45 years and those aged 6-23 months (RR, 1.073; 95% CI, .563-2.046; P = .83). Vaccine seroefficacy was 85% (95% CI, 80%-88%). Conclusion: This is the first field estimate of the seroefficacy of a Vi-TT vaccine and shows that Typbar TCV substantially reduces the number of serologically defined clinical or subclinical infections in infants, children, and adults. These results support the recent World Health Organization recommendations for deployment of typhoid conjugate vaccines in high-burden areas.
RCT Entities:
Background: Salmonella Typhi is the major cause of enteric fever in lower-income countries. New conjugate vaccines show promise as public health interventions, but there are no efficacy data available from endemic areas. Methods: Data were obtained from a previously published phase 3 randomized controlled trial comparing Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TT) with Vi polysaccharide vaccine (Vi-PS) in participants aged 2-45 years. An additional open-label arm administered Vi-TT to children aged 6-23 months. The proportion of participants with presumed clinical or subclinical infection ("seroincidence") was determined using mixture models and compared using relative risks (RRs). Results: Of 387 participants, 81 (21%) were classified as having presumed typhoid infection during the 2-year postvaccination period. Seroincidence was lower in participants randomized to Vi-TT rather than Vi-PS among those aged 2-45 years (RR, 0.372; 95% confidence interval [CI], .235-.588; P < .001) and those aged 2-15 years (RR, 0.424; 95% CI, .231-.778; P = .004). There was no difference in seroincidence for Vi-TT between those aged 2-45 years and those aged 6-23 months (RR, 1.073; 95% CI, .563-2.046; P = .83). Vaccine seroefficacy was 85% (95% CI, 80%-88%). Conclusion: This is the first field estimate of the seroefficacy of a Vi-TT vaccine and shows that Typbar TCV substantially reduces the number of serologically defined clinical or subclinical infections in infants, children, and adults. These results support the recent World Health Organization recommendations for deployment of typhoid conjugate vaccines in high-burden areas.
Authors: Stefan H F Hagmann; Kristina M Angelo; Ralph Huits; Katherine Plewes; Gilles Eperon; Martin P Grobusch; Anne McCarthy; Michael Libman; Eric Caumes; Daniel T Leung; Hilmir Asgeirsson; Mogens Jensenius; Eli Schwartz; Adrian Sánchez-Montalvá; Paul Kelly; Prativa Pandey; Karin Leder; Daniel L Bourque; Yukihiro Yoshimura; Frank P Mockenhaupt; Perry J J van Genderen; Silvia Odolini; Patricia Schlagenhauf; Bradley A Connor; Davidson H Hamer Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: Grace D Appiah; Alexandria Chung; Adwoa D Bentsi-Enchill; Sunkyung Kim; John A Crump; Vittal Mogasale; Rachael Pellegrino; Rachel B Slayton; Eric D Mintz Journal: Am J Trop Med Hyg Date: 2020-06 Impact factor: 2.345
Authors: Caitlin Barkume; Kashmira Date; Samir K Saha; Farah Naz Qamar; Dipika Sur; Jason R Andrews; Stephen P Luby; M Imran Khan; Alex Freeman; Mohammad Tahir Yousafzai; Denise Garrett Journal: J Infect Dis Date: 2018-11-10 Impact factor: 5.226